tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Akari Therapeutics Completes August 2025 Notes Offering

Story Highlights
Akari Therapeutics Completes August 2025 Notes Offering

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from Akari Therapeutics ( (AKTX) ).

Akari Therapeutics successfully completed the issuance of unsecured promissory notes in a private placement, known as the August 2025 Notes Offering, with a total principal amount of approximately $3.8 million. The final tranche of this offering was closed on September 26, 2025, with the company issuing $312,500 in notes for a purchase price of $250,000, marking the completion of the $3 million aggregate purchase price goal.

The most recent analyst rating on (AKTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.

Spark’s Take on AKTX Stock

According to Spark, TipRanks’ AI Analyst, AKTX is a Neutral.

Akari Therapeutics’ stock score of 44 reflects significant challenges due to its current financial instability and lack of revenue. While the technical analysis indicates a neutral trend, the company’s speculative nature due to the absence of traditional valuation metrics underscores the risk. However, the recent positive corporate event with the appointment of a new CEO brings some potential for strategic improvement, slightly offsetting the otherwise high-risk profile.

To see Spark’s full report on AKTX stock, click here.

More about Akari Therapeutics

Average Trading Volume: 177,040

Technical Sentiment Signal: Sell

Current Market Cap: $31.64M

See more data about AKTX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1